title: The effect of reboxetine co-administration with olanzapine on metabolic and endocrine profile in schizophrenia patients.
abstract: BACKGROUND
  We previously demonstrated that the addition of the selective norepinephrine reuptake inhibitor reboxetine attenuates olanzapine-induced weight gain. Using the same study sample, we also sought to determine whether reboxetine's weight-attenuating effect was accompanied by a beneficial effect on metabolic and endocrine parameters relevant to antipsychotic-induced weight gain and obesity.
  
  
  METHODS
  Blood samples at baseline and at the end of the 6-week trial were available for 54 participants who participated in previous double-blind, placebo-controlled studies of reboxetine (4 mg BID) addition to olanzapine-treated schizophrenia patients. Fasting glucose, lipid profile, insulin, leptin, cortisol, dehydroepiandrosterone (DHEA), prolactin, and thyroid-stimulating hormone (TSH) were analyzed.
  
  
  RESULTS
  In contrast to the olanzapine/placebo group, the olanzapine/reboxetine group exhibited a reduction in blood triglyceride (p < 0.05) and leptin (p < 0.05) levels, and elevation in cortisol (p < 0.05) and DHEA (p < 0.008) levels. No significant between-group differences were detected in the changes in cholesterol, glucose, insulin, TSH, and prolactin.
  
  
  CONCLUSIONS
  Reboxetine addition resulted in meaningful improvement of some metabolic and endocrine measures associated with olanzapine-induced weight gain. The potential role of reboxetine in the prevention of olanzapine-induced weight gain and cardio-metabolic morbidity merits further large-scale, long-term investigation.
authors.affiliation: Beer Yakov Mental Health Center affiliated to Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
authors.forename: Avi
authors.initials: A
authors.lastname: Amrami-Weizman
authors.forename: Rachel
authors.initials: R
authors.lastname: Maayan
authors.forename: Irit
authors.initials: I
authors.lastname: Gil-Ad
authors.forename: Artashez
authors.initials: A
authors.lastname: Pashinian
authors.forename: Camil
authors.initials: C
authors.lastname: Fuchs
authors.forename: Moshe
authors.initials: M
authors.lastname: Kotler
authors.forename: Michael
authors.initials: M
authors.lastname: Poyurovsky
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D009025:Morpholines / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D000077152:Olanzapine; D000077593:Reboxetine; D012559:Schizophrenia / Q000188:drug therapy*; D015430:Weight Gain / Q000187:drug effects; D055815:Young Adult
chemical_list: D018759:Adrenergic Uptake Inhibitors; D014150:Antipsychotic Agents; D009025:Morpholines; D001569:Benzodiazepines; D000077593:Reboxetine; D000077152:Olanzapine